A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation
Open Access
- 26 January 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-7
Abstract
The development of specific antiviral compounds to SARS-CoV-2 is an urgent task. One of the obstacles for the antiviral development is the requirement of biocontainment because infectious SARS-CoV-2 must be handled in a biosafety level-3 laboratory. Replicon, a non-infectious self-replicative viral RNA, could be a safe and effective tool for antiviral evaluation. Herein, we generated a PCR-based SARS-CoV-2 replicon. Eight fragments covering the entire SARS-CoV-2 genome except S, E, and M genes were amplified with HiBiT-tag sequence by PCR. The amplicons were ligated and in vitro transcribed to RNA. The cells electroporated with the replicon RNA showed more than 3000 times higher luminescence than MOCK control cells at 24 h post-electroporation, indicating robust translation and RNA replication of the replicon. The replication was drastically inhibited by remdesivir, an RNA polymerase inhibitor for SARS-CoV-2. The IC50 of remdesivir in this study was 0.29 μM, generally consistent to the IC50 obtained using infectious SARS-CoV-2 in a previous study (0.77 μM). Taken together, this system could be applied to the safe and effective antiviral evaluation without using infectious SARS-CoV-2. Because this is a PCR-based and transient replicon system, further improvement including the establishment of stable cell line must be achieved.Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirusProceedings of the National Academy of Sciences, 2013
- Fiji: an open-source platform for biological-image analysisNature Methods, 2012
- Coronavirus N Protein N-Terminal Domain (NTD) Specifically Binds the Transcriptional Regulatory Sequence (TRS) and Melts TRS-cTRS RNA DuplexesJournal of Molecular Biology, 2009
- Construction of a non-infectious SARS coronavirus replicon for application in drug screening and analysis of viral protein functionBiochemical and Biophysical Research Communications, 2008
- Derivation of a novel SARS–coronavirus replicon cell line and its application for anti-SARS drug screeningVirology, 2007
- Construction of a Severe Acute Respiratory Syndrome Coronavirus Infectious cDNA Clone and a Replicon To Study Coronavirus RNA SynthesisJournal of Virology, 2006
- Modular organization of SARS coronavirus nucleocapsid proteinJournal of Biomedical Science, 2005
- Selective Replication of Coronavirus Genomes That Express Nucleocapsid ProteinJournal of Virology, 2005
- Quantification of individual subgenomic mRNA species during replication of the coronavirus transmissible gastroenteritis virusVirus Research, 2000
- Studies on avian infectious bronchitis virus (IBV)Archives of Virology, 1979